Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$2.85 +2.9%	$2.09	$1.10 ▼ $3.24	$158.41M	3.03	226,381 shs	17,913 shs
CRBU Caribou Biosciences	$1.85 +0.5%	$1.72	$0.66 ▼ $3.00	$172.27M	2.55	1.34 million shs	1.40 million shs
DERM Journey Medical	$7.47 +5.5%	$7.15	$3.54 ▼ $8.90	$174.02M	0.8	110,539 shs	239,603 shs
SNTI Senti Biosciences	$1.65 +3.5%	$1.97	$1.46 ▼ $16.94	$43.03M	2.07	173,289 shs	69,190 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	-1.77%	-3.15%	+49.73%	+88.44%	+17.62%
CRBU Caribou Biosciences	+2.22%	-8.00%	-22.36%	+80.39%	-17.49%
DERM Journey Medical	+0.14%	-2.48%	-2.61%	+1.14%	+60.91%
SNTI Senti Biosciences	+0.63%	+3.92%	-20.10%	-50.31%	-38.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLLS Cellectis	3.3705 of 5 stars	3.5	5.0	3.0	2.5	0.0
CRBU Caribou Biosciences	2.8536 of 5 stars	3.5	5.0	1.9	1.7	0.0
DERM Journey Medical	1.6495 of 5 stars	3.2	1.0	2.2	0.8	0.6
SNTI Senti Biosciences	2.9745 of 5 stars	3.5	5.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	3.00	Buy	$4.00	41.34% Upside
CRBU Caribou Biosciences	3.00	Buy	$6.67	255.56% Upside
DERM Journey Medical	2.33	Hold	$11.75	56.56% Upside
SNTI Senti Biosciences	3.00	Buy	$8.50	421.47% Upside

Current Analyst Ratings Breakdown

Latest SNTI, DERM, CRBU, and CLLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	DERM Journey Medical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $13.00
8/8/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/12/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/6/2025	SNTI Senti Biosciences	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$56.30M	2.79	N/A	N/A	$1.75 per share	1.62
CRBU Caribou Biosciences	$9.99M	17.48	N/A	N/A	$1.78 per share	1.05
DERM Journey Medical	$56.40M	3.10	N/A	N/A	$0.83 per share	9.04
SNTI Senti Biosciences	$2.56M	16.66	N/A	N/A	$0.94 per share	1.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$36.76M	-$0.82	N/A	N/A	N/A	-100.69%	-68.05%	-21.53%	11/3/2025 (Estimated)
CRBU Caribou Biosciences	-$149.10M	-$1.78	N/A	N/A	N/A	-1,800.93%	-62.35%	-49.65%	11/5/2025 (Estimated)
DERM Journey Medical	-$14.67M	-$0.38	N/A	N/A	N/A	-15.49%	-48.69%	-11.26%	N/A
SNTI Senti Biosciences	-$52.79M	-$8.95	N/A	N/A	N/A	N/A	-223.98%	-76.02%	N/A

Latest SNTI, DERM, CRBU, and CLLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	-$0.35	+$0.05	-$0.58	$1.64 million	$2.67 million
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
8/7/2025	Q2 2025	SNTI Senti Biosciences	-$0.58	-$0.56	+$0.02	-$0.56	$1.30 million	$0.50 million
8/4/2025	Q2 2025	CLLS Cellectis	-$0.15	-$0.24	-$0.09	-$0.24	$10.07 million	$18.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	0.58	1.38	1.38
CRBU Caribou Biosciences	N/A	6.66	6.66
DERM Journey Medical	1.11	1.27	0.95
SNTI Senti Biosciences	N/A	3.26	3.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
CRBU Caribou Biosciences	77.51%
DERM Journey Medical	7.25%
SNTI Senti Biosciences	25.73%

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
CRBU Caribou Biosciences	8.28%
DERM Journey Medical	15.03%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
CRBU Caribou Biosciences	100	93.12 million	85.41 million	Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
SNTI Senti Biosciences	4	26.16 million	25.34 million	Not Optionable

SNTI, DERM, CRBU, and CLLS Headlines

Recent News About These Companies

Senti Biosciences (NASDAQ:SNTI) Upgraded to Hold at Wall Street Zen

August 19 at 3:13 AM | americanbankingnews.com

Chardan Capital Issues Optimistic Forecast for SNTI Earnings

August 15, 2025 | americanbankingnews.com

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

August 14, 2025 | globenewswire.com

Senti Biosciences Discusses Phase 2 Dose Selection for SENTI-202 in Virtual Investor Segment

August 12, 2025 | quiverquant.comQ

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

August 12, 2025 | globenewswire.com

Senti Biosciences' (SNTI) Buy Rating Reiterated at Chardan Capital

August 11, 2025 | americanbankingnews.com

Senti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML ...

August 8, 2025 | finanznachrichten.de

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

August 7, 2025 | globenewswire.com

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

August 5, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/08/05/3127362/0/en/senti-bio-determines-recommended-phase-2-dose-rp2d-in-phase-1-study-of-senti-202-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-including-acute-myeloid-leukemia.html$

Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 23, 2025 | finance.yahoo.com

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

July 22, 2025 | globenewswire.com

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

July 21, 2025 | globenewswire.com

Senti Biosciences, Inc. Appoints Bryan Baum to Board of Directors

July 18, 2025 | quiverquant.comQ

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

July 18, 2025 | globenewswire.com

NASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.com

July 3, 2025 | investing.com

SNTI - Senti Biosciences Inc Sustainability - Morningstar

July 2, 2025 | morningstar.comM

Senti Biosciences CEO Timothy Lu Highlights Advancements in Gene Circuit Technology at Nasdaq’s Amplify Spotlight Series

June 30, 2025 | quiverquant.comQ

Senti Bio Participates in Nasdaq Amplify Spotlight Series

June 30, 2025 | globenewswire.com

Senti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies - Nasdaq

June 26, 2025 | nasdaq.com

Senti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies

June 24, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, DERM, CRBU, and CLLS Company Descriptions

Cellectis NASDAQ:CLLS

$2.82 +0.05 (+1.81%)

As of 04:00 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Caribou Biosciences NASDAQ:CRBU

$1.85 +0.01 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.85 +0.00 (+0.22%)

As of 05:40 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Journey Medical NASDAQ:DERM

$7.47 +0.39 (+5.51%)

Closing price 04:00 PM Eastern

Extended Trading

$7.49 +0.02 (+0.27%)

As of 04:10 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Senti Biosciences NASDAQ:SNTI

$1.64 +0.06 (+3.46%)

Closing price 04:00 PM Eastern

Extended Trading

$1.64 0.00 (0.00%)

As of 05:23 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time